Amicus Therapeutics (FOLD) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Amicus Therapeutics (NASDAQ: FOLD) in the last few weeks:

  • 10/12/2018 – Amicus Therapeutics had its “hold” rating reaffirmed by analysts at Chardan Capital. They now have a $15.00 price target on the stock.
  • 10/12/2018 – Amicus Therapeutics had its “buy” rating reaffirmed by analysts at Cowen Inc. They now have a $31.00 price target on the stock.
  • 10/8/2018 – Amicus Therapeutics was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $15.00 price target on the stock. According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “
  • 10/6/2018 – Amicus Therapeutics was upgraded by analysts at BidaskClub from a “strong sell” rating to a “sell” rating.
  • 10/4/2018 – Amicus Therapeutics was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “AMICUS THERAPEUTICS is a biopharmaceutical company developing novel, oral therapeutics known as pharmacological chaperones for the treatment of a range of human genetic diseases. Pharmacological chaperone technology involves the use of small molecules that selectively bind to and stabilize proteins in cells, leading to improved protein folding and trafficking, and increased activity. Amicus is initially targeting lysosomal storage disorders, which are severe, chronic genetic diseases with unmet medical needs. Amicus has completed Phase 2 clinical trials of Amigal(TM) for the treatment of Fabry disease and is conducting Phase 2 clinical trials of Plicera(TM) for the treatment of Gaucher disease. “

Shares of NASDAQ:FOLD traded down $0.30 during trading on Friday, hitting $11.99. 145,544 shares of the company’s stock traded hands, compared to its average volume of 3,438,389. Amicus Therapeutics, Inc. has a 52 week low of $11.57 and a 52 week high of $17.62. The company has a debt-to-equity ratio of 0.30, a current ratio of 10.88 and a quick ratio of 10.73. The stock has a market capitalization of $2.43 billion, a PE ratio of -4.11 and a beta of 1.32.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings data on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.33). Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. The business had revenue of $21.31 million for the quarter, compared to analysts’ expectations of $18.92 million. On average, research analysts expect that Amicus Therapeutics, Inc. will post -1.19 earnings per share for the current year.

In other news, major shareholder Life Sciences Maste Perceptive bought 50,000 shares of the company’s stock in a transaction that occurred on Friday, September 21st. The shares were acquired at an average price of $12.53 per share, with a total value of $626,500.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO William D. Baird III sold 10,000 shares of Amicus Therapeutics stock in a transaction that occurred on Monday, October 15th. The shares were sold at an average price of $12.23, for a total value of $122,300.00. Following the completion of the sale, the chief financial officer now directly owns 127,622 shares in the company, valued at approximately $1,560,817.06. The disclosure for this sale can be found here. Insiders have bought a total of 620,000 shares of company stock worth $7,505,000 in the last quarter. 2.90% of the stock is currently owned by company insiders.

Institutional investors have recently made changes to their positions in the stock. Exane Derivatives acquired a new stake in Amicus Therapeutics in the 2nd quarter valued at approximately $137,000. P.R. Herzig & Co. Inc. acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $156,000. Arbor Wealth Management LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $144,000. Quantitative Systematic Strategies LLC acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $179,000. Finally, TCW Group Inc. acquired a new position in shares of Amicus Therapeutics during the 2nd quarter worth approximately $245,000.

Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.

Featured Story: Penny Stocks

Receive News & Ratings for Amicus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply